AI eye doctor: QiLin system aims to sharpen injection decisions

NCT ID NCT07328776

First seen Jan 10, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This study tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. About 200 patients who have completed initial treatment will be randomly assigned to have their injection decisions made by a doctor alone or by a doctor using QiLin. The goal is to see if AI assistance improves the accuracy of treatment decisions compared to expert review.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai general hospital

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai general hospital, Shanghai Jiao Tong University, Shanghai, 200080

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.